Organization (Industry)
Taiho Pharmaceutical (Japan)
ClinicalTrials.gov lists Taiho Pharmaceutical (Japan) as lead sponsor of 43 trials. It has 164 active development programs and 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo 大鵬薬品工業株式会社, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Taiho Pharmaceutical (Japan): 43 lead-sponsored trials and 1 legal-entity registration.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stomach Neoplasms | 15 |
| Colorectal Neoplasms | 14 |
| Pancreatic Neoplasms | 6 |
| Biliary Tract Neoplasms | 3 |
| Breast Neoplasms | 3 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 28 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (164)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| ZIMBERELIMAB | Biliary Tract Neoplasms | Phase 3 | 2 |
| GEMCITABINE | Biliary Tract Neoplasms | Phase 3 | 2 |
| CISPLATIN | Biliary Tract Neoplasms | Phase 3 | 2 |
| Futibatinib | Biliary Tract Neoplasms | Phase 3 | 2 |
| TAS 102 | Colorectal Neoplasms | Phase 3 | 2 |
Showing 5 of 164 active programs.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Tegafur-uracil (UFT) | 3 |
| CISPLATIN | 3 |
| GEMCITABINE | 3 |
| Futibatinib | 2 |
| DURVALUMAB | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 89% hit target (n=9) | 78% on time (n=9) |
Journals published in (44)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 8 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 7 |
| Cancer chemotherapy and pharmacology | 6 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 4 |
| British journal of cancer | 4 |
Showing 5 of 44 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 341 | 39 | 2025-12-09 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 4 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2015-06-05 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Taiho Pharmaceutical Co., Ltd. | Itano-gun, JP | FDA, Health Canada | |
| Taiho Pharmaceutical Co., Ltd. | Kodama-gun, JP | EMA, FDA, Health Canada | |
| Taiho Pharmaceutical Co. Ltd. | Itano, JP | EMA |
Organization relationships (8)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Taiho Oncology (United States) | Co sponsors trial with | 2 |
| Peking University | Co sponsors trial with | 1 |
| Memorial Sloan Kettering Cancer Center | Co sponsors trial with | 1 |
| The University of Hong Kong | Co sponsors trial with | 1 |
| Andrew Ko | Co sponsors trial with | 1 |
Showing 5 of 8 relationships.
Latest dated events (418)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 418 events.
Biomarker capability evidence (123)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 123 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.